Tutkimus saadaksesi lisätietoja siitä, kuinka risankizumabi toimii nuorissa osallistujissa haavaisessa koliitissa (MIGHTY)
Vaiheen 3, monikeskustutkimus risankizumabin farmakokinetiikan, tehokkuuden ja turvallisuuden arvioimiseksi avoimella induktiolla, satunnaistetulla kaksoissokkoudella ja avoimella pitkäaikaisella pidennysjaksoilla lasten koehenkilöillä (2–18-vuotiaita), joissa
Ulcerative colitis (UC) is a type of inflammatory bowel disease that causes inflammation and bleeding from the lining of the rectum and colon (large intestine). This study will assess how Risankizumab moves through the body as well as how safe and effective it is in treating pediatric participants with moderate to severely active UC. Adverse events and change in disease activity will be assessed.
Risankizumab is an approved medication for moderate to severe UC in multiple countries and is being developed for the treatment of UC in pediatrics. This study is comprised of 3 cohorts that may participate in 3 substudies (SS). Cohort 1 will enroll participants with ages from 6 to less than 18 years. Cohort 2 will enroll participants with ages from 2 to less than 6 years. Cohort 3 will enroll participants with ages from 2 to less than 18 years. SS1 is an open-label induction period where participants will receive a weight-based induction regimen of risankizumab. SS2 is a double-blind maintenance period where participants will be randomized to receive 1 of 2 doses of weight-based maintenance regimen of risankizumab. SS3 is an open-label extension period where participants will receive risankizumab based off of their response in SS2. Around 120 pediatric participants with UC will be enrolled at around 80 sites worldwide.
Participants in SS1 will receive risankizumab intravenously during the 12-week induction period. Participants in SS2 will receive risankizumab subcutaneously during the 52-week randomized maintenance period. Participants in SS3 will receive risankizumab subcutaneously during the 208-week open label period. Participants will be followed-up for approximately 140 days.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Tutkimuksen yleiskatsaus
Tila
Interventio / Hoito
Opintotyyppi
Ilmoittautuminen (Arvioitu)
Vaihe
- Vaihe 3
Yhteystiedot ja paikat
Opiskeluyhteys
- Nimi: ABBVIE CALL CENTER
- Puhelinnumero: 844-663-3742
- Sähköposti: abbvieclinicaltrials@abbvie.com
Opiskelupaikat
-
-
-
Brussels, Belgia, 1020
- Rekrytointi
- Hospital Universite Enfants Reine Fabiola /ID# 271860
-
Liège, Belgia, 4000
- Rekrytointi
- Centre Hospitalier Regional de la Citadelle /ID# 270459
-
-
Brussels Capital
-
Brussels, Brussels Capital, Belgia, 1200
- Rekrytointi
- Cliniques Universitaires UCL Saint-Luc /ID# 270123
-
-
-
-
-
São Paulo, Brasilia, 01308-050
- Rekrytointi
- Hospital Sirio Libanes - Sao Paulo /ID# 271818
-
-
Minas Gerais
-
Juiz de Fora, Minas Gerais, Brasilia, 36033-318
- Rekrytointi
- Galileo Medical Research /ID# 271817
-
-
Paraná
-
Curitiba, Paraná, Brasilia, 80250-060
- Rekrytointi
- Hospital Pequeno Principe /ID# 271814
-
-
-
-
A Coruna
-
A Coruña, A Coruna, Espanja, 15006
- Rekrytointi
- Hospital Teresa Herrera - CHUAC /ID# 271459
-
-
Madrid
-
Majadahonda, Madrid, Espanja, 28222
- Rekrytointi
- Hospital Universitario Puerta de Hierro - Majadahonda /ID# 271466
-
-
-
-
Gyeongsangnam-do
-
Yangsan, Gyeongsangnam-do, Etelä -Korea, 50612
- Rekrytointi
- Pusan National University Yangsan Hospital /ID# 272769
-
-
Seoul Teugbyeolsi
-
Seoul, Seoul Teugbyeolsi, Etelä -Korea, 03080
- Rekrytointi
- Seoul National University Hospital /ID# 272852
-
Seoul, Seoul Teugbyeolsi, Etelä -Korea, 06351
- Rekrytointi
- Samsung Medical Center /ID# 272862
-
Seoul, Seoul Teugbyeolsi, Etelä -Korea, 03181
- Rekrytointi
- Kangbuk Samsung Hospital /ID# 273333
-
Seoul, Seoul Teugbyeolsi, Etelä -Korea, 03722
- Rekrytointi
- Yonsei University Health System - Severance Hospital /ID# 272894
-
-
-
-
-
Trieste, Italia, 34137
- Rekrytointi
- Ospedale Infantile Burlo Garofolo /ID# 274442
-
-
Foggia
-
San Giovanni Rotondo, Foggia, Italia, 71013
- Rekrytointi
- Fondazione di Religione e di Culto Casa Sollievo della Sofferenza /ID# 271889
-
-
Napoli
-
Naples, Napoli, Italia, 80131
- Rekrytointi
- Azienda Ospedaliera Universitaria Federico II - Naples /ID# 271895
-
-
Roma
-
Rome, Roma, Italia, 00168
- Rekrytointi
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS-Universita Cattolica /ID# 272967
-
-
-
-
-
Fukushima, Japani, 960-1295
- Rekrytointi
- Fukushima Medical University Hospital /ID# 281178
-
-
Aichi-ken
-
Ōbu, Aichi-ken, Japani, 474-8710
- Rekrytointi
- Aichi Children's Health And Medical Center /ID# 280462
-
-
Chiba
-
Kashiwa-shi, Chiba, Japani, 277-0871
- Rekrytointi
- Tsujinaka Hospital - Kashiwanoha /ID# 280303
-
-
Fukuoka
-
Kurume-shi, Fukuoka, Japani, 830-0011
- Rekrytointi
- Kurume University Hospital /ID# 280792
-
-
Gunma
-
Maebashi, Gunma, Japani, 371-8511
- Rekrytointi
- Gunma University Hospital /ID# 281179
-
-
Hyōgo
-
Kobe, Hyōgo, Japani, 650-0017
- Rekrytointi
- Kobe University Hospital /ID# 281796
-
-
Kumamoto
-
Kumamoto, Kumamoto, Japani, 861-8520
- Rekrytointi
- Japanese Red Cross Kumamoto Hospital /ID# 280696
-
-
Saga-ken
-
Saga, Saga-ken, Japani, 849-8501
- Rekrytointi
- Saga University Hospital /ID# 281232
-
-
Saitama
-
Saitama-shi, Saitama, Japani, 330-8777
- Rekrytointi
- Saitama Children's Medical Center /ID# 280603
-
-
Shizuoka
-
Hamamatsu, Shizuoka, Japani, 431-3192
- Rekrytointi
- Hamamatsu University Hospital /ID# 281614
-
-
Tokyo
-
Bunkyo-ku, Tokyo, Japani, 113-8519
- Rekrytointi
- Institute of Science Tokyo Hospital /ID# 280694
-
Bunkyo-ku, Tokyo, Japani, 113-8431
- Rekrytointi
- Juntendo University Hospital /ID# 280463
-
Fuchu-shi, Tokyo, Japani, 183-8561
- Rekrytointi
- Tokyo Metropolitan Children's Medical Center /ID# 280791
-
Setagaya City, Tokyo, Japani, 157-8535
- Rekrytointi
- National Center For Child Health And Development /ID# 280460
-
-
-
-
Alberta
-
Calgary, Alberta, Kanada, T3B 6A8
- Rekrytointi
- Alberta Children's Hospital /ID# 272635
-
Edmonton, Alberta, Kanada, T6G 2B7
- Rekrytointi
- University of Alberta Hospital /ID# 271168
-
-
Ontario
-
London, Ontario, Kanada, N6A 5W9
- Rekrytointi
- London Health Sciences Centre - Verspeeten Family Cancer Centre /ID# 271157
-
-
-
-
Guangdong
-
Guangzhou, Guangdong, Kiina, 510620
- Rekrytointi
- Guangzhou Medical University Affiliated Women and Children's Medical Center /ID# 277962
-
-
Henan
-
Zhengzhou, Henan, Kiina, 450018
- Rekrytointi
- Henan Children's Hospital Zhengzhou Children's Hospital /ID# 278794
-
-
Hunan
-
Changsha, Hunan, Kiina, 410007
- Rekrytointi
- Hunan Children's Hospital /ID# 278111
-
-
Jilin
-
Changchun, Jilin, Kiina, 130021
- Rekrytointi
- The First Hospital of Jilin University - Changchun /ID# 279290
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, Kiina, 200025
- Rekrytointi
- Ruijin Hospital, Shanghai Jiaotong University School of Medicine /ID# 278113
-
-
Zhejiang
-
Hangzhou, Zhejiang, Kiina, 310018
- Rekrytointi
- Sir Run Run Shaw Hospital of Zhejiang University School of Medicine /ID# 277994
-
Hangzhou, Zhejiang, Kiina, 310056
- Rekrytointi
- The Childrens Hospital of Zhejiang University School of Medicine /ID# 278815
-
-
-
-
-
Thessaloniki, Kreikka, 54642
- Rekrytointi
- General Hospital of Thessaloniki Hippokrateio /ID# 271939
-
-
Attica
-
Athens, Attica, Kreikka, 11527
- Rekrytointi
- Thoracic General Hospital of Athens I Sotiria /ID# 270143
-
Chaïdári, Attica, Kreikka, 12462
- Rekrytointi
- University General Hospital Attikon /ID# 272361
-
-
-
-
Masovian Voivodeship
-
Warsaw, Masovian Voivodeship, Puola, 00-189
- Rekrytointi
- Centrum Zdrowia Mdm /ID# 276942
-
Warsaw, Masovian Voivodeship, Puola, 00-728
- Rekrytointi
- Medical Network Sp. z o.o. /ID# 276903
-
-
Podlaskie Voivodeship
-
Bialystok, Podlaskie Voivodeship, Puola, 15-274
- Rekrytointi
- Uniwersytecki Dzieciecy Szpital Kliniczny im. L. Zamenhofa w Bialymstoku /ID# 276771
-
-
-
-
Stockholm County
-
Solna, Stockholm County, Ruotsi, 171 64
- Rekrytointi
- Karolinska University Hospital Solna /ID# 271679
-
Stockholm, Stockholm County, Ruotsi, 118 83
- Rekrytointi
- Sodersjukhuset /ID# 271678
-
-
Västra Götaland County
-
Gothenburg, Västra Götaland County, Ruotsi, 413 46
- Rekrytointi
- Sahlgrenska Universitetssjukhuset /ID# 271675
-
Ottaa yhteyttä:
- Site Coordinator
- Puhelinnumero: +46313435865
-
-
-
-
Brandenburg
-
Cottbus, Brandenburg, Saksa, 03048
- Rekrytointi
- Medizinische Universitaet Lausitz - Carl Thiem /ID# 272023
-
-
Hesse
-
Kassel, Hesse, Saksa, 34125
- Rekrytointi
- Klinikum Kassel /ID# 271546
-
-
North Rhine-Westphalia
-
Münster, North Rhine-Westphalia, Saksa, 48149
- Rekrytointi
- Universitaetsklinikum Muenster /ID# 271898
-
-
-
-
-
Novi Sad, Serbia, 21000
- Rekrytointi
- Institute for Child and Youth Health Care of Vojvodina /ID# 269961
-
-
Beograd
-
Belgrade, Beograd, Serbia, 11000
- Rekrytointi
- University Children's Hospital /ID# 269960
-
Belgrade-Vračar, Beograd, Serbia, 11000
- Rekrytointi
- Institut za zdravstvenu zastitu majke i deteta Srbije Dr Vukan Cupic /ID# 270696
-
-
-
-
-
Taichung, Taiwan, 407219
- Rekrytointi
- Taichung Veterans General Hospital /ID# 269242
-
Taipei, Taiwan, 100
- Rekrytointi
- National Taiwan University Hospital /ID# 269244
-
-
-
-
-
Liverpool, Yhdistynyt kuningaskunta, L12 2AP
- Rekrytointi
- Alder Hey Children's NHS Foundation Trust /ID# 271533
-
-
Cambridgeshire
-
Cambridge, Cambridgeshire, Yhdistynyt kuningaskunta, CB2 2QQ
- Rekrytointi
- Addenbrookes Hospital /ID# 271489
-
-
England
-
Sheffield, England, Yhdistynyt kuningaskunta, S10 2TH
- Rekrytointi
- Sheffield Children's Hospital NHS Foundation Trust /ID# 271490
-
-
-
-
Arizona
-
Phoenix, Arizona, Yhdysvallat, 85016
- Rekrytointi
- Phoenix Children's Hospital /ID# 273015
-
-
California
-
San Diego, California, Yhdysvallat, 92123
- Rekrytointi
- Rady Children's Hospital /ID# 271873
-
San Francisco, California, Yhdysvallat, 94158
- Rekrytointi
- University of California San Francisco - Mission Bay /ID# 273022
-
-
Florida
-
Miami, Florida, Yhdysvallat, 33155
- Rekrytointi
- Nicklaus Children's Hospital - Miami /ID# 271585
-
-
Georgia
-
Atlanta, Georgia, Yhdysvallat, 30342
- Rekrytointi
- Childrens Center For Digestive Health Care /ID# 273228
-
-
Illinois
-
Chicago, Illinois, Yhdysvallat, 60637
- Rekrytointi
- University of Chicago Medical Center /ID# 271588
-
-
New Jersey
-
Morristown, New Jersey, Yhdysvallat, 07962
- Rekrytointi
- Goryeb Children's Hospital /ID# 271801
-
-
Ohio
-
Cleveland, Ohio, Yhdysvallat, 44106
- Rekrytointi
- University Hospitals Cleveland Medical Center /ID# 271831
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Yhdysvallat, 19104
- Rekrytointi
- The Children's Hospital of Philadelphia /ID# 273222
-
Pittsburgh, Pennsylvania, Yhdysvallat, 15224
- Rekrytointi
- Upmc Children'S Hospital Of Pittsburgh /ID# 272328
-
-
South Carolina
-
Greenville, South Carolina, Yhdysvallat, 29615
- Rekrytointi
- Patewood Medical Campus /ID# 272477
-
-
Texas
-
Dallas, Texas, Yhdysvallat, 75235
- Rekrytointi
- University of Texas - Southwestern Medical Center /ID# 271835
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Kuvaus
Inclusion Criteria:
- Active ulcerative colitis (UC) with an modified Mayo Score (mMS) of 5 to 9 points and endoscopic subscore of 2 to 3 (confirmed by central reader).
- Demonstrated intolerance or inadequate response (IR) to one or more of the following categories of drugs:
aminosalicylates (except in countries where failure of this drug class is not sufficient for eligibility), oral locally acting corticosteroids, systemic steroids (prednisone or equivalent), immunomodulators (IMMs), and/or biologic therapies, as outlined in the protocol.
- Subjects must have a documented history of UC for at least 3 months prior to Baseline, confirmed by colonoscopy during the screening period, with exclusion of current infection, colonic dysplasia and/or malignancy. Documentation of pathology results consistent with the diagnosis of UC must be available.
Exclusion Criteria:
- Participants who have had a major surgery performed within 12 weeks prior to Baseline or planned during the conduct of the study (e.g., inguinal hernia repair, cholecystectomy, intestinal resection).
- Participants who have concurrent clinically significant medical conditions other than the indication being studied or any other reason that the investigator determines would interfere with the subject's participation in this study, would make the subject an unsuitable candidate to receive study treatment, or would put the subject at risk by participating in the study.
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Hoito
- Jako: Satunnaistettu
- Inventiomalli: Peräkkäinen tehtävä
- Naamiointi: Kaksinkertainen
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
|---|---|
|
Kokeellinen: PK Cohort 1: SS1
Cohort 1 will consist of 2 age groups (6 to < 12 years and 12 to < 18 years). SS1 is a 12-week induction period where participants will receive a weight-based dose of risankizumab. All participants who complete SS1 are eligible to enter SS2 |
Risankizumab intravenous (IV) infusion
Muut nimet:
Risankizumab subcutaneous (SC) injection
Muut nimet:
|
|
Kokeellinen: PK Cohort 1: SS2 Dose A
Cohort 1 will consist of 2 age groups (6 to < 12 years and 12 to < 18 years). Participants who complete SS1 will be randomized into a 52-week maintenance phase (SS2) to receive double-blind risankizumab Dose A. Participants who complete SS2 will have the opportunity to enter the open-label long term extension SS3. |
Risankizumab intravenous (IV) infusion
Muut nimet:
Risankizumab subcutaneous (SC) injection
Muut nimet:
|
|
Kokeellinen: PK Cohort 1: SS2 Dose B
Cohort 1 will consist of 2 age groups (6 to < 12 years and 12 to < 18 years). Participants who complete SS1 will be randomized into a 52-week maintenance phase (SS2) to receive double-blind risankizumab Dose B. Participants who complete SS2 will have the opportunity to enter the open-label long term extension SS3. |
Risankizumab intravenous (IV) infusion
Muut nimet:
Risankizumab subcutaneous (SC) injection
Muut nimet:
|
|
Kokeellinen: PK Cohort 1: SS3 Dose A
Cohort 1 will consist of 2 age groups (6 to < 12 years and 12 to < 18 years). SS3 is a 208-week extension period where participants receive risankizumab based on their response in SS2. |
Risankizumab intravenous (IV) infusion
Muut nimet:
Risankizumab subcutaneous (SC) injection
Muut nimet:
|
|
Kokeellinen: PK Cohort 1: SS3 Dose B
Cohort 1 will consist of 2 age groups (6 to < 12 years and 12 to < 18 years). SS3 is a 208-week extension period where participants receive risankizumab based on their response in SS2. |
Risankizumab intravenous (IV) infusion
Muut nimet:
Risankizumab subcutaneous (SC) injection
Muut nimet:
|
|
Kokeellinen: PK Cohort 2: SS1
Cohort 2 will enroll participants aged 2 to less than 6 years. SS1 is a 12-week induction period where participants will receive a weight-based dose of risankizumab. All subjects who complete SS1 are eligible to enter SS2. |
Risankizumab intravenous (IV) infusion
Muut nimet:
Risankizumab subcutaneous (SC) injection
Muut nimet:
|
|
Kokeellinen: PK Cohort 2: SS2 Dose A
Cohort 2 will enroll participants aged 2 to less than 6 years. Participants who complete SS1 will be randomized into a 52-week maintenance phase (SS2) to receive double-blind risankizumab Dose A. Participants who complete SS2 will have the opportunity to enter the open-label long-term extension SS3. |
Risankizumab intravenous (IV) infusion
Muut nimet:
Risankizumab subcutaneous (SC) injection
Muut nimet:
|
|
Kokeellinen: PK Cohort 2: SS2 Dose B
Cohort 2 will enroll participants aged 2 to less than 6 years. Participants who complete SS1 will be randomized into a 52-week maintenance phase (SS2) to receive double-blind risankizumab Dose B. Participants who complete SS2 will have the opportunity to enter the open-label long-term extension SS3. |
Risankizumab intravenous (IV) infusion
Muut nimet:
Risankizumab subcutaneous (SC) injection
Muut nimet:
|
|
Kokeellinen: PK Cohort 2: SS3 Dose A
Cohort 2 will enroll participants aged 2 to less than 6 years. SS3 is a 208-week extension period where participants receive risankizumab based on their response in SS2. |
Risankizumab intravenous (IV) infusion
Muut nimet:
Risankizumab subcutaneous (SC) injection
Muut nimet:
|
|
Kokeellinen: PK Cohort 2: SS3 Dose B
Cohort 2 will enroll participants aged 2 to less than 6 years. SS3 is a 208-week extension period where participants receive risankizumab based on their response in SS2. |
Risankizumab intravenous (IV) infusion
Muut nimet:
Risankizumab subcutaneous (SC) injection
Muut nimet:
|
|
Kokeellinen: Expansion Cohort 3: SS1
Cohort 3 will enroll participants aged 2 to less than 18 years. SS1 is a 12-week induction period where participants will receive a weight-based dose of risankizumab. All participants who complete SS1 are eligible to enter SS2. |
Risankizumab intravenous (IV) infusion
Muut nimet:
Risankizumab subcutaneous (SC) injection
Muut nimet:
|
|
Kokeellinen: Expansion Cohort 3: SS2 Dose A
Cohort 3 will enroll participants aged 2 to less than 18 years. Participants who complete SS1 will be randomized into a 52-week maintenance phase (SS2) to receive double-blind risankizumab Dose A. Participants who complete SS2 will have the opportunity to enter the open-label long term extension SS3. |
Risankizumab intravenous (IV) infusion
Muut nimet:
Risankizumab subcutaneous (SC) injection
Muut nimet:
|
|
Kokeellinen: Expansion Cohort 3: SS2 Dose B
Cohort 3 will enroll participants aged 2 to less than 18 years. Participants who complete SS1 will be randomized into a 52-week maintenance phase (SS2) to receive double-blind risankizumab Dose B. Participants who complete SS2 will have the opportunity to enter the open-label long term extension SS3. |
Risankizumab intravenous (IV) infusion
Muut nimet:
Risankizumab subcutaneous (SC) injection
Muut nimet:
|
|
Kokeellinen: Expansion Cohort 3: SS3 Dose A
Cohort 3 will enroll participants aged 2 to less than 18 years. SS3 is a 208-week extension period where participants receive risankizumab based on their response in SS2. |
Risankizumab intravenous (IV) infusion
Muut nimet:
Risankizumab subcutaneous (SC) injection
Muut nimet:
|
|
Kokeellinen: Expansion Cohort 3: SS3 Dose B
Cohort 3 will enroll participants aged 2 to less than 18 years. SS3 is a 208-week extension period where participants receive risankizumab based on their response in SS2. |
Risankizumab intravenous (IV) infusion
Muut nimet:
Risankizumab subcutaneous (SC) injection
Muut nimet:
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
PK Lead-In Cohort 1: Maximum Observed Serum Concentration (Cmax)
Aikaikkuna: At Week 64
|
Maximum observed plasma concentration (Cmax) |
At Week 64
|
|
PK Lead-In Cohort 2: Maximum Observed Serum Concentration (Cmax)
Aikaikkuna: At Week 64
|
Maximum observed plasma concentration (Cmax) |
At Week 64
|
|
PK Lead-In Cohort 1: Time to Maximum Serum Concentration (Tmax)
Aikaikkuna: At Week 64
|
Time to maximum plasma concentration (Tmax) |
At Week 64
|
|
PK Lead-In Cohort 2: Time to Maximum Serum Concentration (Tmax)
Aikaikkuna: At Week 64
|
Time to maximum plasma concentration (Tmax) |
At Week 64
|
|
PK Lead-In Cohort 1: Area Under the Serum Concentration-Time Curve Over the Dosing Interval (AUCtau)
Aikaikkuna: At Week 64
|
Area under the serum concentration-time curve over the dosing interval (AUCtau) |
At Week 64
|
|
PK Lead-In Cohort 2: Area Under the Serum Concentration-Time Curve Over the Dosing Interval (AUCtau)
Aikaikkuna: At Week 64
|
Area under the serum concentration-time curve over the dosing interval (AUCtau) |
At Week 64
|
|
Expansion Cohort 3: Achievement of Clinical Remission per Modified Mayo Score (mMS) Among Week 12 Clinical Responders per mMS
Aikaikkuna: At Week 64
|
Clinical remission on the mMS is defined as defined as Stool Frequency Subscore (SFS) ≤ 1 and not greater than Baseline, Rectal Bleeding Subscore (RBS) = 0, and Mayo Endoscopic Subscore (MES) ≤ 1 |
At Week 64
|
|
Number of Participants With Adverse Events
Aikaikkuna: Up to 292 Weeks
|
An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. The investigator assessed the relationship of each event to the use of study drug as either probably related, possibly related, probably not related or not related |
Up to 292 Weeks
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Laajennuskohortti 3: Kliinisen remission saavuttaminen mms: lle
Aikaikkuna: Viikolla 12
|
Viikolla 12
|
|
|
Laajennuskohortti 3: Kliinisen vasteen saavuttaminen mms: lle
Aikaikkuna: Viikolla 12
|
Viikolla 12
|
|
|
Laajennuskohortti 3: Endoskooppisen parannuksen saavuttaminen
Aikaikkuna: Viikolla 12
|
Viikolla 12
|
|
|
Laajennuskohortti 3: Oireenmukainen vaste osittaista MMS: tä kohti
Aikaikkuna: Viikolla 12
|
Viikolla 12
|
|
|
Laajennuskohortti 3: Kliinisen vasteen saavuttaminen mms: llä viikon 12 vastaajissa mms /
Aikaikkuna: Viikolla 64
|
Viikolla 64
|
|
|
Laajennuskohortti 3: Endoskooppisen parannuksen saavuttaminen viikon 12 vastaajien keskuudessa mms /
Aikaikkuna: Viikolla 64
|
Viikolla 64
|
|
|
Laajennuskohortti 3: Kortikosteroidittoman kliinisen remission saavuttaminen mms: n kohdalla viikolla 12 vastaajia mm: llä
Aikaikkuna: Viikolla 64
|
Viikolla 64
|
|
|
PK Lead-In Cohort 1: Achievement of corticosteroid-free (at least 90 days without corticosteroid exposure) clinical remission per mMS at Week 64 among Week 12 responders per mMS
Aikaikkuna: Up to Week 64
|
Up to Week 64
|
|
|
PK Lead-In Cohort 2: Achievement of corticosteroid-free (at least 90 days without corticosteroid exposure) clinical remission per mMS at Week 64 among Week 12 responders per mMS
Aikaikkuna: Up to Week 64
|
Up to Week 64
|
|
|
PK Lead-In Cohort 1: Achievement of clinical remission per mMS among Week 12 responders per mMS
Aikaikkuna: At Week 64
|
Clinical remission on the mMS is defined as defined as Stool Frequency Subscore (SFS) ≤ 1 and not greater than Baseline, Rectal Bleeding Subscore (RBS) = 0, and Mayo Endoscopic Subscore (MES) ≤ 1 |
At Week 64
|
|
PK Lead-In Cohort 2: Achievement of clinical remission per mMS among Week 12 responders per mMS
Aikaikkuna: At Week 64
|
Clinical remission on the mMS is defined as defined as Stool Frequency Subscore (SFS) ≤ 1 and not greater than Baseline, Rectal Bleeding Subscore (RBS) = 0, and Mayo Endoscopic Subscore (MES) ≤ 1 |
At Week 64
|
|
PK Lead-In Cohort 1: Achievement of clinical remission per mMS
Aikaikkuna: At Week 12
|
Clinical remission on the mMS is defined as Stool Frequency Subscore (SFS) ≤ 1 and not greater than Baseline, Rectal Bleeding Subscore (RBS) = 0, and Mayo Endoscopic Subscore (MES) ≤ 1 |
At Week 12
|
|
PK Lead-In Cohort 2: Achievement of clinical remission per mMS
Aikaikkuna: At Week 12
|
Clinical remission on the mMS is defined as Stool Frequency Subscore (SFS) ≤ 1 and not greater than Baseline, Rectal Bleeding Subscore (RBS) = 0, and Mayo Endoscopic Subscore (MES) ≤ 1 |
At Week 12
|
|
PK Lead-In Cohort 1: Achievement of clinical response per mMS
Aikaikkuna: At Week 12
|
Clinical response per mMS is defined as decrease in mMS by ≥ 2 points and ≥ 30% from Baseline with a decrease in Rectal Bleeding Subscore (RBS) of ≥ 1 or an absolute RBS of 0 or 1. |
At Week 12
|
|
PK Lead-In Cohort 2: Achievement of clinical response per mMS
Aikaikkuna: At Week 12
|
Clinical response per mMS is defined as decrease in mMS by ≥ 2 points and ≥ 30% from Baseline with a decrease in Rectal Bleeding Subscore (RBS) of ≥ 1 or an absolute RBS of 0 or 1. |
At Week 12
|
|
PK Lead-In Cohort 1: Achievement of endoscopic improvement
Aikaikkuna: At Week 12
|
Endoscopic improvement defined as MES ≤ 1 |
At Week 12
|
|
PK Lead-In Cohort 2: Achievement of endoscopic improvement
Aikaikkuna: At Week 12
|
Endoscopic improvement defined as MES ≤ 1 |
At Week 12
|
|
PK Lead-In Cohort 1: Symptomatic response per partial mMS
Aikaikkuna: At Week 12
|
Symptomatic response per partial mMS is defined as decrease in partial mMS by ≥ 1 points and ≥ 30% from Baseline with decrease in RBS of ≥ 1 or an absolute RBS of 0 or 1. |
At Week 12
|
|
PK Lead-In Cohort 2: Symptomatic response per partial mMS
Aikaikkuna: At Week 12
|
Symptomatic response per partial mMS is defined as decrease in partial mMS by ≥ 1 points and ≥ 30% from Baseline with decrease in RBS of ≥ 1 or an absolute RBS of 0 or 1. |
At Week 12
|
|
PK Lead-In Cohort 1: Achievement of clinical response per mMS among Week 12 responders per mMS
Aikaikkuna: At Week 64
|
Clinical response per mMS is defined as decrease in mMS by ≥ 2 points and ≥ 30% from Baseline with a decrease in Rectal Bleeding Subscore (RBS) of ≥ 1 or an absolute RBS of 0 or 1. |
At Week 64
|
|
PK Lead-In Cohort 2: Achievement of clinical response per mMS among Week 12 responders per mMS
Aikaikkuna: At Week 64
|
Clinical response per mMS is defined as decrease in mMS by ≥ 2 points and ≥ 30% from Baseline with a decrease in Rectal Bleeding Subscore (RBS) of ≥ 1 or an absolute RBS of 0 or 1. |
At Week 64
|
|
PK Lead-In Cohort 1: Achievement of endoscopic improvement among Week 12 responders per mMS
Aikaikkuna: At Week 64
|
Endoscopic improvement defined as MES ≤ 1 |
At Week 64
|
|
PK Lead-In Cohort 2: Achievement of endoscopic improvement among Week 12 responders per mMS
Aikaikkuna: At Week 64
|
Endoscopic improvement defined as MES ≤ 1 |
At Week 64
|
Yhteistyökumppanit ja tutkijat
Sponsori
Tutkijat
- Opintojohtaja: ABBVIE INC., AbbVie
Julkaisuja ja hyödyllisiä linkkejä
Hyödyllisiä linkkejä
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Todellinen)
Ensisijainen valmistuminen (Arvioitu)
Opintojen valmistuminen (Arvioitu)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Avainsanat
Muita asiaankuuluvia MeSH-ehtoja
Muut tutkimustunnusnumerot
- M19-751
- 2024-514695-41-00 (Ctis)
Yksittäisten osallistujien tietojen suunnitelma (IPD)
Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?
IPD-suunnitelman kuvaus
AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.
IPD-jaon aikakehys
For details on when studies are available for sharing, visit https://vivli.org/ourmember/abbvie/
IPD-jaon käyttöoikeuskriteerit
To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
IPD-jakamista tukeva tietotyyppi
- STUDY_PROTOCOL
- MAHLA
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Yhdysvalloissa valmistettu ja sieltä viety tuote
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .